Literature DB >> 26121202

Risk Factors for Measles in HIV-infected Children and Adolescents in Botswana.

Kathleen E Wirth1, Elizabeth R Wolf, David M Goldfarb, Ari Ho-Foster, Michael Tolle, Christina Jacovides, Brianna Kirk, Mamiki Chise, Andrew P Steenhoff.   

Abstract

We conducted a matched case-control study of 566 HIV-infected children in Botswana during a 2009-2010 measles outbreak to identify the risk factors for measles. Children in the oldest age quartile (≥13.1 years) were 4-fold more likely to acquire measles than those in the youngest quartile (<7.1 years). HIV-infected older children and adolescents may benefit from additional measles vaccination.

Entities:  

Mesh：

Year:  2015        PMID： 26121202      PMCID： PMC4570848          DOI： 10.1097/INF.0000000000000816

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  10 in total

1.  Measles outbreaks and progress toward measles preelimination --- African region, 2009-2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-04-01       Impact factor: 17.586

2.  Measles antibody in vaccinated human immunodeficiency virus type 1-infected children.

Authors:  S M Arpadi; L E Markowitz; A L Baughman; K Shah; H Adam; A Wiznia; G Lambert; J Dobroszycki; J L Heath; W J Bellini
Journal:  Pediatrics       Date:  1996-05       Impact factor: 7.124

Review 3.  Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity.

Authors:  Pippa Scott; William J Moss; Zunera Gilani; Nicola Low
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

4.  Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy.

Authors:  L Aurpibul; T Puthanakit; S Siriaksorn; T Sirisanthana; V Sirisanthana
Journal:  HIV Med       Date:  2006-10       Impact factor: 3.180

Review 5.  Measles virus-induced suppression of immune responses.

Authors:  Diane E Griffin
Journal:  Immunol Rev       Date:  2010-07       Impact factor: 12.988

6.  The influence of HIV-1 exposure and infection on levels of passively acquired antibodies to measles virus in Zambian infants.

Authors:  Susana Scott; William J Moss; Simon Cousens; Judy A Beeler; Susette A Audet; Nanthalile Mugala; Thomas C Quinn; Diane E Griffin; Felicity T Cutts
Journal:  Clin Infect Dis       Date:  2007-10-22       Impact factor: 9.079

Review 7.  Severe measles in immunocompromised patients.

Authors:  L J Kaplan; R S Daum; M Smaron; C A McCarthy
Journal:  JAMA       Date:  1992-03-04       Impact factor: 56.272

8.  Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study.

Authors:  William J Moss; Susana Scott; Nanthalile Mugala; Zaza Ndhlovu; Judy A Beeler; Susette A Audet; Mirriam Ngala; Sheila Mwangala; Chansa Nkonga-Mwangilwa; Judith J Ryon; Mwaka Monze; Francis Kasolo; Thomas C Quinn; Simon Cousens; Diane E Griffin; Felicity T Cutts
Journal:  J Infect Dis       Date:  2007-06-19       Impact factor: 5.226

9.  Factors associated with fatal cases of measles. A retrospective autopsy study.

Authors:  A P Beckford; R O Kaschula; C Stephen
Journal:  S Afr Med J       Date:  1985-12-07

10.  Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities.

Authors:  Kaitlin Rainwater-Lovett; Hope C Nkamba; Mwangelwa Mubiana-Mbewe; Carolyn Bolton-Moore; William J Moss
Journal:  J Infect Dis       Date:  2013-08-02       Impact factor: 5.226
  10 in total
  1 in total

1.  The burden of vaccine-preventable diseases among HIV-infected and HIV-exposed children in sub-Saharan Africa: a systematic review and meta-analysis.

Authors:  Olatunji O Adetokunboh; Ajibola Awotiwon; Duduzile Ndwandwe; Olalekan A Uthman; Charles S Wiysonge
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.